Interplay between gut microbiota and intestinal lipid metabolism:mechanisms and implications.
- Author:
Bingqing HANG
1
;
Yuhao WANG
2
Author Information
- Publication Type:Review
- Keywords: Gut microbiota; Lipid absorption; Metabolic disease
- MeSH: Humans; Gastrointestinal Microbiome/physiology*; Lipid Metabolism; Animals; Intestinal Mucosa/metabolism*; Homeostasis; Dysbiosis; Obesity/metabolism*; Intestines/microbiology*; Non-alcoholic Fatty Liver Disease/metabolism*; Metabolic Diseases/metabolism*
- From: Journal of Zhejiang University. Science. B 2025;26(10):961-971
- CountryChina
- Language:English
- Abstract: The gut microbiota is an indispensable symbiotic entity within the human holobiont, serving as a critical regulator of host lipid metabolism homeostasis. Therefore, it has emerged as a central subject of research in the pathophysiology of metabolic disorders. This microbial consortium orchestrates key aspects of host lipid dynamics-including absorption, metabolism, and storage-through multifaceted mechanisms such as the enzymatic processing of dietary polysaccharides, the facilitation of long-chain fatty acid uptake by intestinal epithelial cells (IECs), and the bidirectional modulation of adipose tissue functionality. Mounting evidence underscores that gut microbiota-derived metabolites not only directly mediate canonical lipid metabolic pathways but also interface with host immune pathways, epigenetic machinery, and circadian regulatory systems, thereby establishing an intricate crosstalk that coordinates systemic metabolic outputs. Perturbations in microbial composition (dysbiosis) drive pathological disruptions to lipid homeostasis, serving as a pathogenic driver for conditions such as obesity, hyperlipidemia, and non-alcoholic fatty liver disease (NAFLD). This review systematically examines the emerging mechanistic insights into the gut microbiota-mediated regulation of intestinal lipid metabolism, while it elucidates its translational implications for understanding metabolic disease pathogenesis and developing targeted therapies.
